Communiqués AbbVie Inc.

Actions

ABBV

US00287Y1091

Produits pharmaceutiques

Marché Fermé - NYSE 22:03:50 23/09/2026			Varia. 5j.	Varia. 1 janv.
265,08 ^USD	-0,05%		+0,98%	+16,01%

23/09	Avis d'analystes du jour : Valeo revient en grâce, avis positifs sur Caixa, Hexpol et AXA
22/09	Allergan Aesthetics (AbbVie) lance son programme "AA Signature" aux Etats-Unis

Communiqués

22/09	AbbVie : Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued	PU
22/09	Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach	PR
22/09	AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis	PR
21/09	AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery	PR
18/09	AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026	PR
18/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society Meeting	AQ
18/09	AbbVie - Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	AQ
17/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting	PR
17/09	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	PR
15/09	AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum	AQ
15/09	AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign	PR
15/09	Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit	PR
10/09	AbbVie Declares Quarterly Dividend	PR
10/09	AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine	PR
03/09	AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma	PR
03/09	AbbVie Completes Acquisition of Apogee Therapeutics	PR
03/09	AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	PR
02/09	Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care	PR
01/09	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture	PR
01/09	SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings	PR
31/08	AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference	PR
27/08	AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
21/08	AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline	PR
18/08	AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support	PR
11/08	Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices	PR